AMA Medical Manufacturing signs MoU with ESGN, MicroPharm UK

AMA Medical Manufacturing has recently signed a Memorandum of Understanding (MoU) with Echitab Study Group Nigeria and MicroPharm Ltd UK to introduce a new line of production aimed at producing anti-snake venoms in Nigeria. The Chairman of AMA Medical Manufacturing, Abdulsalami Nasibi, expressed the importance of this partnership in addressing the critical issue of snake bites, especially in endemic communities in Northern Nigeria. The signing of the MoU marks a significant step towards ensuring self-reliance and strengthening the healthcare sector in Nigeria. The impact of this partnership is crucial in combating the rising cases of snake bites in the country, which have led to increased morbidity and mortality rates. The scarcity of anti-venom products in Nigeria, coupled with the reluctance of foreign manufacturers to continue production due to market limitations, has prompted the need for local production. AMA Medical Manufacturing aims to bridge this gap by initiating technology transfer and scaling up production not only for Nigeria but also for the broader African market. In terms of investment and plant adjustments, the size of the deal with Echitab Study Group Nigeria and MicroPharm Ltd UK signifies a significant commitment towards ensuring the success of the anti-snake venom production project. The Chairman highlighted the importance of maintaining the momentum generated by the research and development phase, emphasizing the urgency to address the escalating human-snake contact as the population grows. By localizing manufacturing processes, Nigeria can secure a sustainable supply of life-saving anti-venom products to meet the growing demand. The expansion of AMA Medical Manufacturing's production offerings to include anti-snake venoms aligns with Nigeria's broader healthcare goals of enhancing medical industrialization and catering to the healthcare needs of the African continent. The collaboration with Echitab Study Group Nigeria and MicroPharm Ltd UK underscores a strategic partnership aimed at bolstering the country's pharmaceutical manufacturing capabilities and ensuring the availability of essential healthcare products. As Nigeria progresses towards achieving self-sufficiency in healthcare production, the production of anti-snake venoms represents a pivotal milestone in addressing public health challenges and improving healthcare outcomes. The MoU signing between AMA Medical Manufacturing, Echitab Study Group Nigeria, and MicroPharm Ltd UK signifies a collaborative effort to enhance medical manufacturing capabilities and contribute to the advancement of the healthcare sector in Nigeria and beyond.